Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.
Aim(s): To describe the use of Chemo and MoAb in GCAs.
Materials and methods: Data from all consecutive patients (pts) with inoperable GCA (1999-2019) were retrospectively collected. Kaplan-Meier, log-rank test and univariate (UV)/multivariable Cox regression analyses (MVA) were performed (survival analysis).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Jorge Barriuso
, Martin A
, Chakrabarty B
, Burghel G
, Lamarca A
, Kamposioras K
, McNamara M
, Clouston H
, Hubner R
, O’Dwyer S
, Wallace A
, Valle J W
To read results and conclusion, please login ...
Further abstracts you may be interested in